Johnson & Johnson Innovative Medicine at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
Johnson & Johnson Innovative Medicine takes part in 6 sessions at CTAD 2026 in Boston. Its program centres on posdinemab, its anti-tau antibody, and what its phase 2 results show for tau PET, fluid biomarkers and cognition. Its work also covers scalable biomarkers for prescreening in preclinical Alzheimer's disease.
| Organization | CTAD 2026 Attendance |
|---|---|
Johnson & Johnson Innovative Medicine New Brunswick, New Jersey | ◇Silver Sponsor |
Johnson & Johnson's pharmaceutical business; its Alzheimer's work includes the anti-tau antibody posdinemab and blood biomarkers for early detection. | Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Talk Tue Nov 17 8:30am–9:10am Talk Tue Nov 17 8:30am–9:10am Session Tue Nov 17 8:30am–9:10am Poster Wed Nov 18 7:15am–5:30pm Poster Wed Nov 18 7:15am–5:30pm |
Instantly find 20 buyers from Johnson & Johnson Innovative Medicine
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction